Armata receives $3.7M defense funding for AP-SA02 Phase 3
Armata Pharmaceuticals received an additional $3.7 million in non-dilutive support from the U.S. Department of War to advance the Phase 3 development of its phage therapy candidate AP-SA02.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed